Daré Bioscience Initiates Phase 1/2 Clinical Study of DARE-HRT1
SAN DIEGO, April 12, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced the initiation of a Phase 1/2 clinical study of DARE-HRT1.
- SAN DIEGO, April 12, 2022 (GLOBE NEWSWIRE) -- DarBioscience, Inc. (NASDAQ: DARE), a leader in womens health innovation, today announced the initiation of a Phase 1/2 clinical study of DARE-HRT1.
- Baseline-corrected steady state release level data from the prior Phase 1 study demonstrate that both dose versions of DARE-HRT1 successfully delivered two different bio-identical hormones over the 28-day evaluation period.
- Dar Bioscience is a biopharmaceutical company committed to advancing innovative products for womens health.
- Dar cautions you that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements.